Nicki Vasquez - 24 Sep 2021 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role
Chief Port. Strat & Alnce Ofcr
Signature
/s/ Edward C. Albini as attorney-in-fact for Nicki Vasquez
Issuer symbol
STRO
Transactions as of
24 Sep 2021
Net transactions value
-$112,396
Form type
4
Filing time
28 Sep 2021, 18:59:39 UTC
Previous filing
11 Aug 2021
Next filing
01 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STRO Common Stock Options Exercise $0 +5,969 +82% $0.000000 13,239 24 Sep 2021 Direct
transaction STRO Common Stock Tax liability $39,671 -2,063 -16% $19.23 11,176 24 Sep 2021 Direct F1
transaction STRO Common Stock Sale $72,724 -3,906 -35% $18.62 7,270 28 Sep 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STRO Restricted Stock Unit (RSU) Options Exercise $0 -5,969 -100% $0.000000* 0 24 Sep 2021 Common Stock 5,969 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.47 to $19.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F5 The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.